GlassScriptPhysician profile
Souad S Youssef
NPI 1922202563
$6,305.10
in general payments reported to CMS, 2019-2025
20 companies · $1,422 in 2025
The $1,422 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $527 · 2020: $573 · 2021: $863 · 2022: $1,021 · 2023: $1,077 · 2024: $822 · 2025: $1,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,320.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,419.91 | 2021-2025 | Avycaz, Mavyret, Dalvance |
| Merck Sharp & Dohme LLC | $760.31 | 2019-2025 | Delstrigo, Pifeltro, Zerbaxa |
| Shionogi INC | $752.50 | 2020-2025 | Fetroja |
| Cumberland Pharmaceuticals, INC. | $534.10 | 2021-2025 | Vibativ |
| Paratek Pharmaceuticals, INC. | $499.73 | 2020-2025 | Nuzyra |
| Allergan, INC. | $455.22 | 2019-2020 | |
| Insmed, INC. | $399.26 | 2019-2024 | Arikayce |
| Viiv Healthcare Company | $298.14 | 2019-2025 | Dovato, Cabenuva |
| Gilead Sciences, INC. | $236.95 | 2019-2025 | Biktarvy |
| Emd Serono, INC. | $208.88 | 2021-2025 | Serostim |
| Astellas Pharma US INC | $207.76 | 2019-2021 | |
| Melinta Therapeutics, LLC | $185.61 | 2019-2025 | Kimyrsa, Orbactiv, Rezzayo |
| Aimmune Therapeutics, INC. | $76.22 | 2024-2025 | Vowst |
| La Jolla Pharmaceutical Company | $66.11 | 2023-2024 | Xerava, Xacduro |
| Ferring Pharmaceuticals INC. | $55.10 | 2025 | Rebyota |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $42.74 | 2019-2021 | |
| Tetraphase Pharmaceuticals, INC. | $37.78 | 2019 | |
| Urgo Medical North America, LLC | $25.56 | 2025 | Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap |
| Organogenesis INC. | $23.22 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Souad Youssef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.